Helix vs SOPHiA GENETICS (2026)
Two genomics platforms selling to health systems with different units of work. Helix is population scale infrastructure: institutions run programs on it, sequence once and return to that data for later clinical and research questions, with payers and life sciences as secondary buyers. SOPHiA is analysis infrastructure for the laboratory, applying patented algorithms to call, annotate and interpret variants from sequencing the institution already performs. The choice follows the ambition. A health system enrolling a population and planning to reuse those genomes for a decade is buying what Helix sells, and inherits a consent problem it must solve before the first sample. A laboratory that wants better interpretation on the work it already does is buying what SOPHiA sells, and the commitment is far smaller.
- It is built for population genomics at health system scale, with institutions running programs on the platform rather than ordering individual tests, and payers and life sciences as adjacent buyers.
- Sequence once and reuse is the architectural argument, which changes the economics of genomics from a per test cost into an asset the institution holds.
- The interoperability position is oriented to enterprise deployment rather than to a laboratory workflow, which is what a population program actually requires.
- The platform is aimed at the laboratory doing the interpretation, applying patented algorithms to call, annotate and interpret variants across the institution's own sequencing.
- Cloud native delivery with a long established analysis product suits a laboratory that wants capability rather than a program, and does not require a population scale commitment.
- Public listing brings financial disclosure obligations that matter when a laboratory workflow will depend on the vendor for years.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Helix and SOPHiA GENETICS are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Helix | SOPHiA GENETICS |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2015 | 2011 |
| Headquarters | San Mateo, California | Boston, Massachusetts |
| Website | helix.com | sophiagenetics.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Helix
-
Product / capability
Helix launched Helix Research Workspaces, a Trusted Research Environment inside Helix Explorer built on the Databricks Data + AI platform, giving approved partners governed compute, storage and analysis tools over more than 550,000 GenoSphere clinicogenomic records (Exome+ data linked to 13+ years of EHR history plus claims).
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory. Helix sells clinical genetic tests (hereditary cancer, cardiovascular, pharmacogenomics, carrier screening, rare disease exome) orderable inside Epic, runs population genomics programs for about 20 health systems including Cone Health, Sanford Health, WellSpan, St. Luke's, HealthPartners, Nebraska Medicine and Memorial Hermann, and sells research access to GenoSphere, a dataset of more than 550,000 exomes linked to an average of 13 years of OMOP-harmonized EHR history and claims.
Source: AI Health Index, August 2026
Cloud genomics analysis company (NASDAQ: SOPH) based in Rolle, Switzerland and Boston. The SOPHiA DDM platform takes sequencing data a laboratory generates in house and calls, annotates and pre-classifies variants with in-house models (PEPPER for small variants, copy number, microsatellite instability and fusion callers, the GIInger deep learning score for genomic instability, and supervised pathogenicity pre-classification), with radiomics and multimodal modules alongside.
Source: AI Health Index, August 2026
Questions buyers ask
How do Helix and SOPHiA GENETICS work with the EHR?
The providers page says clinicians can order Helix tests inside their EHR and that Helix integrates with Epic so results appear where they practice, with embedded clinical decision support and pharmacogenomic results returned in minutes from stored sequence. On the research side, GenoSphere's clinical data is harmonized to the OMOP common data model and refreshed quarterly, so analyses carry across to other datasets built the same way.
With SOPHiA GENETICS, the platform page and flyer describe seamless, automated data transfer between technologies, EHR, LIMS and interpretation tools, and the company describes the platform as technology agnostic across sequencing instruments, which is what lets laboratories keep the sequencers they own. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Helix and SOPHiA GENETICS priced and sold?
In Helix's case, clinical tests are billed to Medicare, Medicaid and commercial insurance, with a cash-pay price offered on request, a financial assistance program and monthly payment plans; family variant testing is free within 90 days of a relative's report. Health plans can buy Helix Genomic Advantage, described as one sequence at one cost with reusable results.
For SOPHiA GENETICS, the annual report states the company earns revenue on a pay-per-analysis basis, with application and product pricing, the access model and customer size also affecting revenue, and describes bundle solutions that pair the platform with third party products in the testing workflow. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Helix and SOPHiA GENETICS handle patient data?
With Helix, the GenoSphere connector returns only de-identified aggregate statistics, suppresses small counts automatically and works only through provisioned partner accounts, which blocks the usual attack of narrowing a cohort to one person.
In SOPHiA GENETICS's case, the flyers describe how anonymized insights are shared, not what an institution can opt out of. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Helix and SOPHiA GENETICS cover?
Helix sells clinical genetic tests (hereditary cancer, cardiovascular, pharmacogenomics, carrier screening, rare disease exome) validated in its laboratory, population screening programs run by about 20 health systems, and research data and tools for life sciences, where the AI sits. The AI tools are scoped to research feasibility and explicitly not to clinical diagnosis or patient management.
With SOPHiA GENETICS, the platform serves hospital and laboratory genomics in oncology (solid tumors, blood cancers, hereditary cancers, liquid biopsy, HRD) and rare and inherited disorders, with radiomics and multimodal modules for research, across more than 990 institutions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Population genomics raises a consent question that neither vendor's material fully resolves and that a health system must answer before either platform is deployed: a sequence generated once and reused for future clinical and research purposes requires a consent model that anticipates uses not yet defined, and participants cannot revoke a genome once it is shared.
Ancestral representation applies to both, since interpretation quality depends on reference data drawn disproportionately from European ancestry populations. Neither publishes pricing in a form that allows comparison, and the commercial shapes differ enough, per program against per analysis, that a like for like figure will not exist.